Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Total Assets of $913.17 million for the year ending 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +0.3% in Total Assets from 2024 to 2025.
- This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $76.8 thousand | Q3 2012: $28.7 thousand | Q1 2013: $28.3 thousand | Q2 2013: $597.7 thousand | Q3 2013: $168.6 thousand | Q1 2014: $18.08 million | Q2 2014: $18.54 million | Q3 2014: $17.42 million | Q1 2015: $113.54 million | Q2 2015: $114.74 million | Q3 2015: $112.22 million | Q1 2016: $100.77 million | Q2 2016: $193.54 million | Q3 2016: $182.33 million | Q1 2017: $155.39 million | Q2 2017: $138.01 million | Q3 2017: $173.97 million | Q1 2018: $307.25 million | Q2 2018: $284.75 million | Q3 2018: $270.83 million | Q1 2019: $461.50 million | Q2 2019: $435.92 million | Q3 2019: $395.75 million | Q1 2020: $288.30 million | Q2 2020: $817.57 million | Q3 2020: $782.29 million | Q1 2021: $750.57 million | Q2 2021: $852.79 million | Q3 2021: $828.83 million | Q1 2022: $701.25 million | Q2 2022: $610.88 million | Q3 2022: $545.92 million | Q1 2023: $824.77 million | Q2 2023: $757.29 million | Q3 2023: $852.32 million | Q1 2024: $869.83 million | Q2 2024: $964.32 million | Q3 2024: $991.12 million | Q1 2025: $966.74 million | Q2 2025: $907.44 million | Q3 2025: $904.95 million.
- Over the full 16 years of available data (2010 to 2025), IOVANCE BIOTHERAPEUTICS, INC.'s Total Assets has grown by 62,405.1%.
- Historical annual values: Fiscal year 2025: $913.17 million | Fiscal year 2024: $910.43 million | Fiscal year 2023: $780.35 million | Fiscal year 2022: $663.98 million | Fiscal year 2021: $777.33 million | Fiscal year 2020: $768.46 million | Fiscal year 2019: $344.66 million | Fiscal year 2018: $480.82 million | Fiscal year 2017: $155.37 million | Fiscal year 2016: $171.89 million | Fiscal year 2015: $105.65 million | Fiscal year 2014: $46.51 million | Fiscal year 2013: $19.87 million | Fiscal year 2012: $29.4 thousand | Fiscal year 2011: $568.4 thousand | Fiscal year 2010: $1.46 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: